GlaxoSmithKline Short Long Term Debt Total from 2010 to 2024

GSK Stock   1,342  32.50  2.48%   
GlaxoSmithKline PLC's Short and Long Term Debt Total is increasing over the years with slightly volatile fluctuation. Short and Long Term Debt Total is expected to dwindle to about 11 B. During the period from 2010 to 2024 GlaxoSmithKline PLC Short and Long Term Debt Total annual values regression line had geometric mean of  13,801,117,145 and mean square error of 45811537.3 T. View All Fundamentals
 
Short and Long Term Debt Total  
First Reported
1986-06-30
Previous Quarter
16.9 B
Current Value
16.1 B
Quarterly Volatility
9.1 B
 
Black Monday
 
Oil Shock
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check GlaxoSmithKline PLC financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among GlaxoSmithKline PLC's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 B, Interest Expense of 502.2 M or Total Revenue of 19.9 B, as well as many indicators such as . GlaxoSmithKline financial statements analysis is a perfect complement when working with GlaxoSmithKline PLC Valuation or Volatility modules.
  
This module can also supplement various GlaxoSmithKline PLC Technical models . Check out the analysis of GlaxoSmithKline PLC Correlation against competitors.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in GlaxoSmithKline Stock

GlaxoSmithKline PLC financial ratios help investors to determine whether GlaxoSmithKline Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GlaxoSmithKline with respect to the benefits of owning GlaxoSmithKline PLC security.